Genetic Immunity is an innovative biotech-nology company focusing on the development of nanomedicine based Therapeutic Vaccines against infection diseases and cancer.

Genetic Immunity is a US/Hungarian biotech-nology company developing Nanomedicines for global unmet medical needs. Based on our proprietary Nanomedicine Vaccine Technology, Nanomedicine Formulation and DermaPrep Targeted Delivery System, we are developing Immune Therapies against infectious diseases, cancer and allergies. more»

News Higlights

» July 27, 2010
NatureNews.com: Therapeutic HIV vaccines show promise

» July 26, 2010
Importance of Therapeutic HIV Vaccine

Latest Press Release

»   July 19, 2010
Immunacia's Genetic Immunity Reports Phase II Data on DermaVir, a Therapeutic Vaccine for HIV/AIDS, During the XVIII International AIDS Conference: A 70% Viral Load Reduction Demonstrated in HIV Drug-naïve Individuals
( Click here to read the press release... )

Recent Projects

» Clinical Trial: DermaVir Patch
Our first Phase II, placebo control-led, double blinded clinical trial is ongoing in Hamburg, Germany, and all patients are enrolled. more»

» DermaPrep Medical Device
CE Mark was obtained for our DermaPrep transdermal delivery device ...

» Nanomedicine Our Nanomedicine Antigen Composition (Nanomedicine) technology creates pathogen-like intelligent nanoparticles from antigens (e.g. pDNA, proteins, peptides) to mimic a pathogen exposure. more»